




COVID-19 serology

Even more reliable with a two-step strategy





Combined sensitivity

Days after onset of symptoms or positive direct detection	n	1. EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG) 2. EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG)			
		positive	borderline	negative	Sensitivity
≤ 10	16	13	0	3	81.3%
> 10	58	51	2	5	91.1%

Borderline results are not included in the calculation of specificity and sensitivity.

Combined specificity

Panel	n	1. EUROIMMUN Anti-SARS-CoV-2 NCP ELISA (IgG) 2. EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG)			
		positive	borderline	negative	Specificity
Blood donors	849	0	0	849	100%
Pregnant women	99	0	0	99	100%
Children	90	0	0	90	100%
Older patients	97	0	0	97	100%
Antibodies against influenza (freshly vacc., incl. courses)	40	0	0	22	100%
Acute EBV infection & heterophile antibodies	22	0	0	40	100%
Rheumatoid factors	40	0	0	40	100%
Total	1,237	0	0	1,237	100%

Order information

Analysis step	Product name	Order numbers	
1. Screening	Anti-SARS-CoV-2 NCP ELISA (IgG)	EI 2606-9601-2 G	EI 2606-9620-2 G *
2. Confirmation	Anti-SARS-CoV-2 ELISA (IgG)	EI 2606-9601 G	EI 2606-9620 G *

* Optimised kit format for high-throughput analytics with the EUROLabWorkstation ELISA